Interim Results of a Clinical Trial for the Treatment of Pain
24 March, 2010
Brainsway is pleased to announce that it has received interim results from a double-blind for the treatment of diabetic chronic neuropathic pain that was performed by Advanced Technologies Innovation Distribution SRL (“Atid”), the distributor of Brainsway’s products in Italy.
The interim results are for 8 patients who underwent two series of treatments using Brainsway’s Deep TMS device, with a one-month gap between series. Each series of treatments consisted of 5 daily treatment sessions.
The effects of the treatment were assessed with accepted questionnaires for the measurement of pain (such as the visual analog scale, the McGill Pain Questionnaire, the Neuropathic Pain Symptom Inventory, the MMPI, etc.) immediately after the treatment and again three weeks later. Analysis of these assessments revealed a significant improvement in pain sensation among patients in the real TMS treatment group, with no such effect in the control group.